2 Under-the-Radar Biotech Stocks to Buy in 2022
Popularity isn't a guarantee of success in the stock market. Some well-known companies can be lousy investment choices while lesser-known ones can boast much more promising prospects. That's why it's worth looking past the hype to dig deeper and find stocks that may not be household names but are worth investing in.
With that as a backdrop, let's consider two biotech stocks that don't grab a lot of headlines but deserve serious consideration: Incyte (NASDAQ: INCY) and Axsome Therapeutics (NASDAQ: AXSM).
Incyte is a drugmaker with a particular focus on the field of oncology. Its best-selling product is called Jakafi, which treats some types of bone marrow cancer, among other conditions. Jakafi generates the bulk of Incyte's revenue.
Source Fool.com
